{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:15:53Z","timestamp":1794107753356,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41375-025-02582-x","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T16:42:19Z","timestamp":1743525739000},"page":"1196-1205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-9288","authenticated-orcid":false,"given":"Gloria","family":"Iacoboni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-0251","authenticated-orcid":false,"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5581-6950","authenticated-orcid":false,"given":"Tom","family":"van Meerten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rampotas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana \u00c1frica","family":"Mart\u00edn-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Benzaqu\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Reguera-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Carpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Roddie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-5596","authenticated-orcid":false,"given":"Lucia","family":"L\u00f3pez-Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Delgado-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Landwehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5072-5013","authenticated-orcid":false,"given":"Sophia","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Silva de Tena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Abrisqueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0221-1835","authenticated-orcid":false,"given":"Janneke","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-1028","authenticated-orcid":false,"given":"Alejandro","family":"Martin Garcia-Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Hernani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-7774","authenticated-orcid":false,"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-9469","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"2582_CR1","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1). Blood. 2023.","DOI":"10.1182\/blood.2022018893"},{"key":"2582_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023;389:148\u201357.","journal-title":"N Engl J Med"},{"key":"2582_CR3","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403\u201315.","journal-title":"Lancet Oncol"},{"key":"2582_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024;143:404\u201316.","journal-title":"Blood"},{"key":"2582_CR5","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294\u2013308.","journal-title":"Lancet"},{"key":"2582_CR6","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal Clin Oncol. 2020;38:3119\u201328.","journal-title":"Journal Clin Oncol"},{"key":"2582_CR7","doi-asserted-by":"crossref","unstructured":"Kwon M, Iacoboni G, Reguera JL, Corral LL, Morales RH, Ortiz-Maldonado V, et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2022.","DOI":"10.3324\/haematol.2022.280805"},{"key":"2582_CR8","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1200\/JCO.19.02103","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, et al. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020;38:3095\u2013106.","journal-title":"J Clin Oncol"},{"key":"2582_CR9","doi-asserted-by":"crossref","unstructured":"Rejeski K, Perez A, Iacoboni G, Penack O, B\u00fccklein V, Jentzsch L, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J Immunother Cancer. 2022;10.","DOI":"10.1136\/jitc-2021-004475"},{"key":"2582_CR10","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1182\/blood.2022016226","volume":"140","author":"A Ali","year":"2022","unstructured":"Ali A, Goy A, Dunleavy K. CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights. Blood. 2022;140:1461\u20139.","journal-title":"Blood"},{"key":"2582_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"Project IN-HsLPF","year":"1993","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394Project IN-HsLPF.","journal-title":"N Engl J Med"},{"key":"2582_CR12","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3324\/haematol.2011.041277","volume":"96","author":"D Villa","year":"2011","unstructured":"Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica. 2011;96:1002\u20137.","journal-title":"Haematologica"},{"key":"2582_CR13","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1182\/blood.2023020911","volume":"144","author":"M Roschewski","year":"2024","unstructured":"Roschewski M, Phelan JD, Jaffe ES. Primary large B-cell lymphomas of immune-privileged sites. Blood. 2024;144:2593\u2013603.","journal-title":"Blood"},{"key":"2582_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/ejh.13968","volume":"111","author":"O Beyar Katz","year":"2023","unstructured":"Beyar Katz O, Perry C, Grisariu-Greenzaid S, Yehudai-Ofir D, Luttwak E, Avni B, et al. Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study. Eur J Haematol. 2023;111:63\u201371.","journal-title":"Eur J Haematol"},{"key":"2582_CR15","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D\u2019Aveni-Piney M, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4:5607\u201315.","journal-title":"Blood Adv"},{"key":"2582_CR16","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"2582_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"2582_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"2582_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrg2918","volume":"12","author":"AL Barab\u00e1si","year":"2011","unstructured":"Barab\u00e1si AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56\u201368.","journal-title":"Nat Rev Genet"},{"key":"2582_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2582_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382.","journal-title":"Blood"},{"key":"2582_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2582_CR23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/cyto.b.21941","volume":"100","author":"J Demaret","year":"2021","unstructured":"Demaret J, Varlet P, Trauet J, Beauvais D, Grossemy A, H\u00e9go F, et al. Monitoring CAR T-cells using flow cytometry. Cytometry B Clin Cytom. 2021;100:218\u201324.","journal-title":"Cytometry B Clin Cytom"},{"key":"2582_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/1097-0320(20001215)42:6<327::AID-CYTO1000>3.0.CO;2-F","volume":"42","author":"B Brando","year":"2000","unstructured":"Brando B, Barnett D, Janossy G, Mandy F, Autran B, Rothe G, et al. Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. European Working Group on Clinical Cell Analysis. Cytometry. 2000;42:327\u201346.","journal-title":"Cytometry"},{"key":"2582_CR25","doi-asserted-by":"publisher","first-page":"830773","DOI":"10.3389\/fimmu.2022.830773","volume":"13","author":"A Peinelt","year":"2022","unstructured":"Peinelt A, Bremm M, Kreyenberg H, Cappel C, Banisharif-Dehkordi J, Erben S, et al. Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel. Front Immunol. 2022;13:830773.","journal-title":"Front Immunol"},{"key":"2582_CR26","unstructured":"R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing 2008. http:\/\/www.r-project.org\/."},{"key":"2582_CR27","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28:2145\u201354.","journal-title":"Nat Med"},{"key":"2582_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood.2020005112","volume":"137","author":"S Bobillo","year":"2021","unstructured":"Bobillo S, Joffe E, Lavery JA, Sermer D, Ghione P, Noy A, et al. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Blood. 2021;137:39\u201348.","journal-title":"Blood"},{"key":"2582_CR29","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bjh.18209","volume":"198","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, et al. A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience. Br J Haematol. 2022;198:492\u2013502.","journal-title":"Br J Haematol"},{"key":"2582_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006401","volume":"11","author":"MM Melssen","year":"2023","unstructured":"Melssen MM, Sheybani ND, Leick KM, Slingluff CL. Barriers to immune cell infiltration in tumors. Journal Immunother Cancer. 2023;11. e006401.","journal-title":"Journal Immunother Cancer"},{"key":"2582_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature"},{"key":"2582_CR32","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937\u201347.","journal-title":"N Engl J Med"},{"key":"2582_CR33","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313\u201323.","journal-title":"N Engl J Med"},{"key":"2582_CR34","doi-asserted-by":"crossref","unstructured":"Locke FL, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P, et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat Med. 2024.","DOI":"10.1038\/s41591-023-02754-1"},{"key":"2582_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","volume":"16","author":"N Epperla","year":"2023","unstructured":"Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, et al. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023;16:111.","journal-title":"J Hematol Oncol"},{"key":"2582_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","volume":"7","author":"MR Cook","year":"2023","unstructured":"Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023;7:32\u20139.","journal-title":"Blood Adv"},{"key":"2582_CR37","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","volume":"94","author":"C Houillier","year":"2020","unstructured":"Houillier C, Soussain C, Ghesqui\u00e8res H, Soubeyran P, Chinot O, Taillandier L, et al. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology. 2020;94:e1027\u2013e39.","journal-title":"Neurology"},{"key":"2582_CR38","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.3324\/haematol.2023.282875","volume":"108","author":"C Lacan","year":"2023","unstructured":"Lacan C, Caron J, Tarantino N, Fouquet B, Cherai M, Parizot C, et al. CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes. Haematologica. 2023;108:3485\u201390.","journal-title":"Haematologica"},{"key":"2582_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01065-z","volume":"14","author":"L Mart\u00edn-Mart\u00edn","year":"2024","unstructured":"Mart\u00edn-Mart\u00edn L, Guti\u00e9rrez-Herrero S, Herrero-Garc\u00eda M, Mart\u00edn Garc\u00eda-Sancho A, Yeguas A, Mart\u00edn-L\u00f3pez A, et al. Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients. Blood Cancer J. 2024;14. 83.","journal-title":"Blood Cancer J"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02582-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02582-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02582-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:46:29Z","timestamp":1746531989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02582-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2582"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02582-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"11 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GI Consultancy and Honoraria: Novartis, Roche, Kite\/Gilead, Bristol-Myers Squibb, Abbvie, Janssen, Sandoz, Miltenyi, AstraZeneca. KR Kite\/Gilead: Honoraria, research funding and travel support; Novartis: Honoraria; BMS\/Celgene: Consultancy, Honoraria. Pierre-Fabre: Travel support. CR Honoraria from Kite\/Gilead, Novartis, BMS, Amgen, Autolus, Janssen, Cellistic, Miltenyi. JD Honoraria from Kite-Gilead, Novartis, Bristol Myers Squibb, Janssen. CC Regeneron: Consultancy\/Advisory, BMS: Consultancy\/Advisory, Takeda: Consultancy\/Advisory\/Honoraria, Novartis: Honoraria. PA Honoraria from Roche, AbbVie, Gilead, BMS, AstraZeneca, Janssen, Incyte. AMGS Honoraria and or consulting fees: Abbvie, AstraZeneca, BeiGene, BMS, Genmab, Gilead \/ Kite, GSK, Ideogen, Incyte, Janssen, Kyowa Kirin, Lilly, Miltenyi, Regeneron, Roche, Sobi, Takeda. Research support: Gilead \/ Kite. RH Research: Gilead. Travel support: Gilead. Honoraria: Gilead, Janssen. MK Consulting and lectures: Gilead, Jazz, Pfizer. MS receives industry research support from Amgen, Bristol-Myers Squibb\/Celgene, Gilead, Janssen, Miltenyi Biotec, Morphosys, Novartis, Roche, Seattle Genetics, and Takeda, and serves as a consultant\/advisor to AvenCell, CDR-Life, Ichnos Sciences, Incyte Biosciences, Janssen, Molecular Partners, and Takeda. She serves on the speakers\u2019 bureau at Amgen, AstraZeneca, BMS\/Celgene, Gilead, GSK, Janssen, Novartis, Pfizer, Roche, and Takeda. M.O. Honoraria: Kite, Novartis, Janssen. Advisory Board: Kite, Autolus. PB Allogene: Honoraria; Amgen: Honoraria; BMS: Honoraria; Kite\/Gilead: Honoraria; Janssen: Honoraria; Jazz Pharmaceuticals: Honoraria; Miltenyi: Honoraria; Novartis: Honoraria; Nektar: Honoraria.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}